NeoGenomics, Inc. (NEO) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $8.68. It has a SharesGrow Score of 50/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of NEO = $45.37 (+422.7% from the current price, the stock appears undervalued). Analyst consensus target is NEO = $14 (+55.5% upside).
Valuation: NEO trades at a trailing Price-to-Earnings (P/E) of -1.9 (S&P 500 average ~25).
Financials: revenue is $727M, +12.6%/yr average growth. Net income is $108M (loss), growing at +4.1%/yr. Net profit margin is -14.9% (negative). Gross margin is 38.8% (+1.9 pp trend).
Balance sheet: total debt is $472M against $837M equity (Debt-to-Equity (D/E) ratio 0.56, moderate). Current ratio is 4.26 (strong liquidity). Debt-to-assets is 34.7%. Total assets: $1.4B.
Analyst outlook: 21 / 29 analysts rate NEO as buy (72%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 63/100 (Pass), Past 0/100 (Fail), Health 50/100 (Partial), Moat 40/100 (Fail), Future 85/100 (Pass), Income 10/100 (Fail).
